Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: it’s a let’s take a profit Friday

October 22, 2021 7:41am

Sector earnings start next week as all three major averages are on track to close the week higher for three-straight weeks of gains

Pre-open indications: 5 SELLs into Strength and with 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity! My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.21% (+73 points), S&P futures are UP +0.13% (+6 point) and NASDAQ futures are DOWN -0.1% (+21 point)

Futures tied to the S&P 500 were lower and mixed in Friday’s pre-open trading,

European stocks were barely higher

Asia-Pacific stocks were also mixed with some muted

Economic data docket: jobless claims and home sales

Henry’omics:

In Thursday’s session, the S&P 500 (+0.03%) notched both a fresh intraday high, a new record close and its seventh consecutive positive session. The Nasdaq rose 0.6%, while the Dow shed -0.02%.

In October, all three indexes are up at least 5%.

Interesting Note: Vaccine advisers to the US Centers for Disease Control and Prevention voted on Thursday to recommend booster doses of both the Moderna and Johnson & Johnson (JNJ) Covid-19 vaccines.

The FDA gave emergency use authorization Wednesday for booster doses of Moderna's (MRNA) and Johnson & Johnson's Janssen vaccines.
The FDA also authorized a mix and match approach -- saying eligible people could get any vaccine as a booster, regardless of which vaccine they got for the initial immunization.

The CDC's Advisory Committee members agreed that people who got JNJ's vaccine need a second vaccination, as that vaccine is less effective than MRNA's and Pfizer’s (PFE) in preventing infection.

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Thursday’s evening’s recap: “expectation or causation. Investors are troubled about reports that inflation pressures are eroding margins and what that may mean for the stock market.” … https://www.regmedinvestors.com/articles/12149

Q4: October, 7 positive and 8 negative closes

Q3/21:

September, 1 holiday, 10 positive and 10 negative close
August - 12 positive and 10 negative close
July: 6 positives, 1 holiday and 15 negative closes

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed down -$0.095 with 265 shares traded after Wednesday’s +$0.30 with 8,356 shares traded after being flat at $3.00 with 1,488 shares traded after Monday’s -$0.065 with 4,041 shares traded, Friday’s -$0.035 with 528 shares traded, and last Thursday’s flat at $3.13 with 22 shares traded after last Wednesday’s +$0.09 with 3,492 shares traded – WOW.

For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

SELL into Strength:

Alnylam Pharmaceuticals (ALNY) closed up +$0.43 to $204.33 after Wednesday’s -$2.77, Tuesday’s +$2.69 and Monday’s -$4.66) with a negative -$4.33 or -2.12% aftermarket indication. A 52-week high of $212.00 and low of $119.29 with a 52-week change of +51.76% and earnings release on 10/28 next Thursday.

Global Blood Therapeutics (GBT) closed up +$1.64 to $31.36 After Wednesday’s $29.79, Tuesday’s $30.31, Monday’s $30.71 and last Friday’s $30.52 with a negative -$0.04 or +0.13% pre-open indication,

Sage Therapeutics (SAGE) closed up +$0.33 to $41.23 after Wednesday’s +$0.61 to $40.90 with a positive +$0.27 or +0.65% aftermarket indication,

Pluristem (PSTI) closed up +$0.26 to $2.99 after Wednesday’s +$0.08 to $2.71 with a positive -$0.07 or +2.34% pre-open indication,

Ultragenyx Pharmaceuticals (RARE) closed up +$1.44 to $78.40 after Wednesday’s -$1.08 with a negative -$0.03 or -0.04% aftermarket indication

The BOTTOM LINE: Don't forget about earnings season – starts next week. It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.

As I stated, it was time to profit … before declines!

The stem, cell and gene therapy earnings will be beginning 10/28 Thursday with Alnylam Pharmaceuticals leading the releases with Sage Therapeutics (SAGE) on 11/2, Vericel (VCEL) on 11/9 and Athersys ATHX) coming 11/15 (to date).

What changes, there is too much uncertainty, that doesn’t appeal to my continued skepticism …

Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of upcoming earnings releases that are coming …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.